BY OUR PLATFORMS
BY THERAPEUTIC AREA
21 July 2016
ZeClinics has been officially granted to be part of the next BIO Business Mission to Japan for the pharmaceutical and biotechnology sector.
The Catalan Governmental Agency for Companies Competitiveness (ACCIÓ) and the Association of Catalan Biotechnology (BIOCAT) have launched the recent call to select strategic Catalan Biotech and Pharma firms and participate in a Japanese Mission. Its aim is to grow the Catalan Trade and Investment name in the second biggest pharmaceutical market worldwide!!!
We are very proud to be one of the few companies representing the Catalan BioRegion, bringing our zebrafish-based INNOVATION to Japan. ZeClinics is already present in the Region through a partnership with the Japanese firm Synphatec Japon Co., Ltd. promoting ZeClinics services for safety and efficacy drug discovery with zebrafish in the Japanese area.
Our aim is to expand the number of research contract signed with Japanese Biotech and Pharma companies and establish long-lasting and collaborative R&D projects, from new platforms development up to collaborative drug discovery.
The Mission will be divided in a 3-days European Biotech and Pharma Partnering Conference in Osaka and the 3-days BioJapan International Fair of Biotechnology in Yokohama. The Osaka region counts with one of the main Bio/Pharma cluster in Japan and the BioJapan is considered the reference Asiatic convention in the field.
ZeClinics will be represented by our Chief Executive Officer, Dr. Davide D’Amico, who will actively search for new local business development collaborators and final B2B meetings with new potential clients.
Both the public agencies and private companies from the Catalan Region merge their efforts and resources to boost economy through international collaborations and business activities.
More info at ACCIÓ, ACCIÓ Japanese office, at BIOCAT and at ZeClinics.